Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

66.39
+0.06000.09%
Post-market: 66.390.00000.00%19:30 EDT
Volume:531.07K
Turnover:35.23M
Market Cap:3.20B
PE:-27.60
High:67.16
Open:66.23
Low:64.00
Close:66.33
52wk High:72.64
52wk Low:9.63
Shares:48.16M
Float Shares:27.63M
Volume Ratio:1.07
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4052
EPS(LYR):-2.3824
ROE:-33.17%
ROA:-22.08%
PB:7.81
PE(LYR):-27.87

Loading ...

MBX Biosciences posts ENDO 2026 canvuparatide presentation update

Reuters
·
Jun 12

MBX Biosciences announces results from Avail, canvuparatide trials

TIPRANKS
·
Jun 12

BRIEF-Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism

Reuters
·
Jun 12

MBX Biosciences says Phase 2 data show once-weekly canvuparatide sustains 57% responder rate at one year in hypoparathyroidism

Reuters
·
Jun 12

Mbx Biosciences - 90% of Patients in Ole Remained in Study at One Year

THOMSON REUTERS
·
Jun 12

Mbx Biosciences - Canvuparatide Well Tolerated With No New Safety Signals During One-Year Ole

THOMSON REUTERS
·
Jun 12

Mbx Biosciences - Responder Rate 57% at One Year Ole, 63% at 12 Weeks Phase 2 Avail Trial

THOMSON REUTERS
·
Jun 12

Mbx Biosciences - Phase 3 Pivotal Trial for Canvuparatide on Track to Initiate in Q3 2026

THOMSON REUTERS
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), MBX Biosciences, Inc. (MBX) and GoodRx Holdings (GDRX)

TIPRANKS
·
Jun 10

Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)

TIPRANKS
·
Jun 09

MBX Biosciences Shareholders Approve Directors and Auditor

TIPRANKS
·
Jun 05

MBX Biosciences shareholders elect Patrick Heron, Edward Mathers as Class II directors

Reuters
·
Jun 05

Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors?

Simply Wall St.
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and MBX Biosciences, Inc. (MBX)

TIPRANKS
·
Jun 05

MBX Biosciences reports one-year Phase 2 extension data for once-weekly canvuparatide at ENDO 2026

Reuters
·
Jun 01

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

GlobeNewswire
·
Jun 01

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

GlobeNewswire
·
May 26

LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)

TIPRANKS
·
May 16

Mbx Biosciences Inc : Stifel Raises Target Price to $56 From $50

THOMSON REUTERS
·
May 12

MBX Biosciences price target raised to $86 from $76 at Citizens

TIPRANKS
·
May 12